Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Medtronic raised its fiscal 2027 profit and revenue growth forecasts, fueled by surging demand for its cardiovascular devices. The company's pulsed field ablation portfolio — used to treat irregular heart rhythms — saw a remarkable 88% jump in sales. Shares climbed over 9% in premarket trading as Medtronic beat Wall Street estimates across all business segments.
Medtronic is riding a cardiovascular wave. The Ireland-based medical device giant raised the lower end of its fiscal 2027 profit forecast and bumped up its annual organic revenue growth outlook to 7.25%–7.75%, up from its prior 6.75%–7.25% projection. The upgrade comes on the back of strong demand for its heart devices, particularly those used in complex cardiovascular procedures.
The company's Q1 revenue hit $9.76 billion — well above the $9.55 billion analysts expected — and it beat earnings estimates across every segment. Its cardiovascular unit, the company's largest, was the standout performer, with sales surging 19.5% to $3.93 billion. Medtronic also announced an $80 million investment in heart valve repair startup Pi-Cardia (with an option to acquire for $210 million) and a $700 million stake in surgical robotics firm Cornerstone Robotics.
By the Numbers:
Why it matters: Medtronic's results reflect a broader industry trend — physicians are rapidly adopting minimally invasive cardiac technologies, signaling growing confidence in next-generation heart care tools and strong near-term demand across the medical device sector.
